ENTERO THERAPEUTICS INC (ENTO) Stock Price, Quote, News and Overview
NASDAQ:ENTO - Nasdaq - US33749P4081 - Common Stock - Currency: USD
ENTO Quote, Performance and Key Statistics
0.5507
-0.01 (-1.66%)
The current stock price of ENTO is 0.5507 USD. In the past month the price increased by 9.05%.
ENTO Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 21.17 | 378.30B | ||
| AMGN | AMGEN INC | 16.39 | 174.51B | ||
| GILD | GILEAD SCIENCES INC | 25.47 | 146.22B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1683.76 | 125.39B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.5 | 77.34B | ||
| ARGX | ARGENX SE - ADR | 231.21 | 36.10B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 31.66B | ||
| ONC | BEIGENE LTD-ADR | N/A | 26.47B | ||
| BNTX | BIONTECH SE-ADR | N/A | 26.08B | ||
| BIIB | BIOGEN INC | 9.13 | 22.01B | ||
| NTRA | NATERA INC | N/A | 19.02B | ||
| GMAB | GENMAB A/S -SP ADR | 24.89 | 15.34B |
Related stock screener links
About ENTO
Company Profile
First Wave Biopharma, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of non-systemic therapies for the treatment of gastrointestinal diseases. The company is headquartered in Boca Raton, Florida and currently employs 9 full-time employees. The company went IPO on 2016-10-11. Its programs address unmet needs in GI health and include latiglutenase, a Phase III-ready, oral biotherapeutic designed to aid gluten digestion and potentially reduce symptoms of celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for multiple GI conditions, including gastroparesis, and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency. The firm also intends to develop Niclosamide, an oral small molecule anti-inflammatory inhibitor therapy for the treatment of ulcerative proctitis and ulcerative proctosigmoiditis, and immune checkpoint inhibitor-associated colitis and diarrhea in metastatic cancer patients.
Company Info
ENTERO THERAPEUTICS INC
777 Yamato Road, Suite 502
Boca Raton FLORIDA US
Employees: 9
Company Website: https://enterothera.com/
Investor Relations: https://www.firstwavebio.com/investors/
Phone: 15615897020
ENTERO THERAPEUTICS INC / ENTO FAQ
What is the stock price of ENTERO THERAPEUTICS INC today?
The current stock price of ENTO is 0.5507 USD. The price decreased by -1.66% in the last trading session.
What is the ticker symbol for ENTERO THERAPEUTICS INC stock?
The exchange symbol of ENTERO THERAPEUTICS INC is ENTO and it is listed on the Nasdaq exchange.
On which exchange is ENTO stock listed?
ENTO stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for ENTERO THERAPEUTICS INC stock?
6 analysts have analysed ENTO and the average price target is 36.72 USD. This implies a price increase of 6567.88% is expected in the next year compared to the current price of 0.5507. Check the ENTERO THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ENTERO THERAPEUTICS INC worth?
ENTERO THERAPEUTICS INC (ENTO) has a market capitalization of 2.62M USD. This makes ENTO a Nano Cap stock.
How many employees does ENTERO THERAPEUTICS INC have?
ENTERO THERAPEUTICS INC (ENTO) currently has 9 employees.
What are the support and resistance levels for ENTERO THERAPEUTICS INC (ENTO) stock?
ENTERO THERAPEUTICS INC (ENTO) has a support level at 0.49 and a resistance level at 0.56. Check the full technical report for a detailed analysis of ENTO support and resistance levels.
Should I buy ENTERO THERAPEUTICS INC (ENTO) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ENTO, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ENTO, evaluating the profitability, health, valuation and growth aspects
- ENTERO THERAPEUTICS INC (ENTO) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ENTERO THERAPEUTICS INC (ENTO) Sales and EPS estimates to see what analysts future expectations are.
- ENTERO THERAPEUTICS INC (ENTO) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ENTERO THERAPEUTICS INC (ENTO) Insider and Institutional Ownership to learn about the owners and their transactions.
- ENTERO THERAPEUTICS INC (ENTO) Stock Chart to make your own analysis
- ENTERO THERAPEUTICS INC (ENTO) Latest news and press-releases to stay up to date.
Does ENTERO THERAPEUTICS INC (ENTO) stock pay dividends?
ENTO does not pay a dividend.
When does ENTERO THERAPEUTICS INC (ENTO) report earnings?
ENTERO THERAPEUTICS INC (ENTO) will report earnings on 2025-03-27, after the market close.
What is the Short Interest ratio of ENTERO THERAPEUTICS INC (ENTO) stock?
The outstanding short interest for ENTERO THERAPEUTICS INC (ENTO) is 3.05% of its float. Check the ownership tab for more information on the ENTO short interest.
ENTO Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to ENTO.
ENTO Financial Highlights
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
ENTO Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 43% to ENTO. The Buy consensus is the average rating of analysts ratings from 6 analysts.